 | | Vol. 13.22 – 8 June, 2021 |
| |
|
|
| The authors showed that MSCs singly coated with a soft conformal gel presenting defined chemomechanical cues promoted matrix remodeling by secreting soluble interstitial collagenases in response to the presence of tumor necrosis factor-alpha.
[Nature Biomedical Engineering] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Speckle-type POZ protein (SPOP) and OTU domain-containing protein 7A (OTUD7A) were identified as the bona fide E3 ligase and deubiquitinase, respectively, that control Ewing sarcoma breakpoint region 1-Friend leukemia integration 1 (EWS–FLI1) protein turnover in Ewing sarcoma.
[Advanced Science] |
|
|
|
| Using fibro-adipogenic progenitors as a model, researchers identified Prdm16 as a nuclear envelope protein that anchored H3K9-methylated chromatin in a cell-specific manner.
[Science Advances] |
|
|
|
| The authors reported the fine surface editing of MSC-exosomes by the metabolic glycoengineering of adipose-derived stem cells to target activated macrophages in the inflamed joints of rheumatoid arthritis.
[Science Advances] |
|
|
|
| Adipose-derived MSCs were loaded with citric acid-coated superparamagnetic iron oxide nanoparticles, systemically transplanted, and magnetically recruited to the injured sciatic nerve.
[Acta Biomaterialia] |
|
|
|
| Researchers reported on the development of an enhanced synergistic combination therapy comprising polyacetal–curcumin nanoconjugate and neural stem cells derived from induced pluripotent stem cells + MSCs treatment as a treatment option for severe sub-acute traumatic spinal cord injury.
[International Journal of Molecular Sciences] |
|
|
|
| Scientists evaluated OxiumTMEXO, a regulatory complying medium, with respect to production capacity and conservation of the extracellular vesicle’s characteristics and functionality and the parental cell’s phenotype and viability.
[Frontiers in Bioengineering and Biotechnology] |
| |
|
|
| Investigators showed that mice with Nsd1 deficiency in Prx1+ mesenchymal progenitors but not in Col2+ chondrocytes showed impaired skeletal growth and fracture healing accompanied by decreased chondrogenic differentiation.
[Bone Research] |
|
|
|
| The authors tested the hypothesis that autologous bone-marrow-(BM) MSC administration in type 2 diabetes patients was safe and that the efficacy of the treatment was dependant on the quality of the autologous BM-MSC population and administration routes.
[Stem Cells Translational Medicine] |
|
|
|
| Researchers investigated the survival and migration of MSC transplanted by various routes in order to identify the best delivery approach that provided an accumulation of therapeutic cells to the injured pancreas in the non-obese diabetic mouse.
[Cell Death & Disease] |
|
|
|
| Investigators showed that conditional knockout of the demethylase Alkbh5 in bone marrow MSCs strengthened bone mass in mice.
[Cell Death & Disease] |
|
|
|
| Two separate dextran sulfate sodium and 2,4,6-trinitrobenzenesulfonic acid-induced inflammatory bowel disease mouse models were intraperitoneally administered MSCs-Exo extracted from human umbilical cord MSC culture supernatant.
[Stem Cell Research & Therapy] |
|
|
|
|
| Scientists describe the advances in fat tissue engineering applied to regenerative surgery, through the use of adipose-derived-MSCs, stromal vascular fraction contained in lipofilling/fat graft in wound healing and scar treatment.
[Stem Cell Research & Therapy] |
|
|
|
| The authors focus on the reasons why articular cartilage (AC) cannot regenerate itself in spite of potential self-repair capacity and summarize the latest developments of the three key components in the field of endogenous AC regeneration.
[Aging and Disease] |
|
|
|
|
| Cynata Therapeutics Limited announced the execution of a worldwide exclusive license agreement with TekCyte Pty Ltd in respect of TekCyte’s wound dressing technology. TekCyte has developed proprietary surface modification technologies to produce polymer-coated dressings for the delivery of MSCs to wounds.
[Cynata Therapeutics Limited (Globe Newswire, Inc.)] |
|
|
|
| Novartis AG has announced the first published mature overall survival and updated overall response rate data following treatment with Tabrecta® in adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14).
[Novartis AG] |
|
|
|
|
| September 13 – 15, 2021
Virtual |
|
|
|
|
|
| | Hannover Medical School – Hannover, Germany |
|
|
|
| | Sana Biotechnology – Multiple Locations, United States |
|
|
|
| | Bio-Techne – Minneapolis, Minnesota, United States |
|
|
|
| | Cincinnati Children’s Hospital Medical Center – Cincinnati, Ohio, United States |
|
|
|
| | H. Lee Moffitt Cancer Center – Tampa, Florida, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
